Literature DB >> 9517610

Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines.

P Lesprit1, B Godeau, F J Authier, M Soubrier, M Zuber, C Larroche, J P Viard, B Wechsler, R Gherardi.   

Abstract

POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome is a rare variant of plasma cell dyscrasia with multiple systemic manifestations. We followed the progress of 20 patients with POEMS syndrome in our institution over a 10-yr period. Pulmonary hypertension (PH) was observed in five patients. All patients suffered dyspnea on exertion, which always appeared during an exacerbation of POEMS syndrome. The typical echocardiographic signs of PH were observed in all of these patients, and the median pulmonary-artery systolic pressure was 57 mm Hg (range, 50 to 65 mm Hg). Mean pulmonary-artery pressure during right side heart catheterization in two patients was 32 mm Hg. No other explanation for the PH could be found. Overproduction of cytokines was found in all cases, with high serum concentrations of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and vascular endothelial growth factor. We suggest that PH should be added to the list of symptoms of POEMS syndrome. Cytokines may mediate POEMS syndrome-associated PH, as proposed for the other systemic manifestations of this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517610     DOI: 10.1164/ajrccm.157.3.9707095

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  27 in total

1.  Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury.

Authors:  Ozlem U Gurkan; Chaoxia He; Rachel Zielinski; Hamid Rabb; Landon S King; Jeffrey M Dodd-o; Franco R D'Alessio; Neil Aggarwal; David Pearse; Patrice M Becker
Journal:  Exp Lung Res       Date:  2011-11-01       Impact factor: 2.459

Review 2.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

3.  Sildenafil and steroid therapy effectively improved POEMS syndrome-associated pulmonary arterial hypertension.

Authors:  Yoshimitsu Shimomura; Masahiko Hara; Isamu Mizote; Yoshikazu Nakaoka; Hirokazu Tanaka; Yoshihiro Asano; Yasushi Sakata; Issei Komuro
Journal:  Int J Hematol       Date:  2010-12-04       Impact factor: 2.490

4.  An unusual case of pulmonary hypertension in a young male.

Authors:  Carlo Rostagno; Stefania Ciolli; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

5.  T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension.

Authors:  E D Austin; M T Rock; C A Mosse; C L Vnencak-Jones; S M Yoder; I M Robbins; J E Loyd; B O Meyrick
Journal:  Respir Med       Date:  2009-10-31       Impact factor: 3.415

6.  Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature.

Authors:  Wayne L Feyereisn; Eric R Fenstad; Robert B McCully; Martha Q Lacy
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

7.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

8.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

9.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

10.  The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.

Authors:  Lakshmi Kugathasan; Julie Basu Ray; Yupu Deng; Effat Rezaei; Daniel J Dumont; Duncan J Stewart
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.